Kenvue's Distribution Challenges Pose a Near-Term Threat, but Our Long-Term Outlook Is Favorable
Despite the large debt balance compared with its current level of cash, we expect healthy cash generation from Kenvue to meet all of its near-term financial obligations. Only $1.5 billion of debt is ...
STAT2d
What happens when a rare disease drug seems to work, but the health care system doesn’t?
Cristina Brennan can hear the clock ticking. At the end of the year, her 12-year-old son Tristan will no longer have free ...
Drug Similar to Ozempic Failed to Treat Parkinson’s Disease in a Trial
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
Medscape4d
AstraZeneca Sues Generic Drugmakers, Claims Cancer Drug Patent Violations
AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...
studyfinds5d
Journavx: What to know about new FDA-approved non-opioid pain medication
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
A first in 25 years: FDA approves new type of painkiller
The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...